

# Developing the Polish Educational Needs Assessment Tool (Pol-ENAT) in rheumatoid arthritis and systemic sclerosis: a cross-cultural validation study using Rasch analysis

Matylda Sierakowska · Stanisław Sierakowski ·  
Justyna Sierakowska · Mike Horton ·  
Mwidimi Ndosi

Accepted: 10 September 2014  
© The Author(s) 2014. This article is published with open access at Springerlink.com

## Abstract

**Objectives** To undertake cross-cultural adaptation and validation of the educational needs assessment tool (ENAT) for use with people with rheumatoid arthritis (RA) and systemic sclerosis (SSc) in Poland.

**Methods** The study involved two main phases: (1) cross-cultural adaptation of the ENAT from English into Polish and (2) Cross-cultural validation of Polish Educational Needs Assessment Tool (Pol-ENAT). The first phase followed an established process of cross-cultural adaptation of self-report measures. The second phase involved completion of the Pol-ENAT by patients and subjecting the data to Rasch analysis to assess the construct validity,

unidimensionality, internal consistency and cross-cultural invariance.

**Results** An adequate conceptual equivalence was achieved following the adaptation process. The dataset for validation comprised a total of 278 patients, 237 (85.3 %) of which were female. In each disease group (145, RA and 133, SSc), the 7 domains of the Pol-ENAT were found to fit the Rasch model,  $X^2(df) = 16.953(14)$ ,  $p = 0.259$  and  $8.132(14)$ ,  $p = 0.882$  for RA and SSc, respectively. Internal consistency of the Pol-ENAT was high (patient separation index = 0.85 and 0.89 for SSc and RA, respectively), and unidimensionality was confirmed. Cross-cultural differential item functioning (DIF) was detected in some subscales, and DIF-adjusted conversion tables were calibrated to enable cross-cultural comparison of data between Poland and the UK.

**Conclusion** Using a standard process in cross-cultural adaptation, conceptual equivalence was achieved between the original (UK) ENAT and the adapted Pol-ENAT. Fit to the Rasch model, confirmed that the construct validity, unidimensionality and internal consistency of the ENAT have been preserved.

**Electronic supplementary material** The online version of this article (doi:10.1007/s11136-014-0805-6) contains supplementary material, which is available to authorized users.

M. Sierakowska  
Department of Integrated Medical Care, Medical University  
of Białystok, Białystok, Poland

S. Sierakowski  
Department of Rheumatology and Internal Diseases, Medical  
University of Białystok, Białystok, Poland

J. Sierakowska  
Department of English Literature, University of Białystok,  
Białystok, Poland

M. Horton · M. Ndosi  
Academic Department of Rehabilitation Medicine, Leeds  
Institute of Rheumatic and Musculoskeletal Medicine,  
University of Leeds, Leeds, UK

M. Ndosi (✉)  
School of Healthcare, University of Leeds, Leeds LS2 9JT, UK  
e-mail: M.E.Ndosi@Leeds.ac.uk

**Keywords** Rheumatoid arthritis · Systemic sclerosis ·  
Patient education · Needs assessment · Cross-cultural  
validation · Rasch analysis

## Introduction

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by the presence of a destructive polyarthritis with a predisposition for affecting the peripheral joints [1]. Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by small-

vessel vasculopathy, autoantibody production and excessive collagen deposition in the skin and internal organs [2]. Both RA and SSc are chronic disabling diseases, which have a negative impact on individuals' physical, social and psychological functioning [3–5].

People with RA and SSc have many and varied needs, and so in addition to offering specific drug treatments and therapies, patient education is recommended as an integral part of the disease management [6]. Most patients with rheumatic diseases believe in the value of patient education and health professionals; especially, nurses spend a considerable amount of their time in providing patient education [7–9].

Patient education is an interactive process between patients and health professionals aimed at supporting and enabling patients to manage their life with arthritis and optimizing their health and well-being [10]. The effects of patient education can be difficult to demonstrate in randomized controlled trials although there is growing evidence that patients' needs and individual learning capabilities play an important role [9–12]. In chronic diseases, patients' perspective of their educational needs is important since they have experiential knowledge about their disease and they undertake daily self-care activities. Patients' expectations determine whether patient education is likely to lead to behavioural change [13]; therefore, it is extremely important for health professionals to assess patient's educational needs and priorities before providing education. This assessment will help tailor education to meet patient's priorities and promote shared decision-making.

Although it is widely accepted that effective patient education has to be targeted to meet the patient's needs and expectations [14–16], our literature search found only one tool for assessing educational needs of patients with rheumatic diseases: the educational needs assessment tool—ENAT [17], which was developed in the UK. The tool has been adapted into other eight European languages (Austrian German, Dutch, Italian, Finnish, Norwegian, Portuguese, Spanish and Swedish) and validated in RA, SSc and other rheumatic conditions [18, 19], but there was no Polish version of the questionnaire.

For a questionnaire to be used in two different cultures, it must be shown to demonstrate conceptual and measurement equivalence. *Conceptual equivalence* can be defined as similarities in the way abstract, latent concepts are interpreted among different cultural groups [20]. To achieve this in the questionnaires adaptation, different guidelines have been proposed, most of which involve a rigorous iterative 'forward–backward' translation process, review of the translations and testing on a sample of patients [21–24]. Measurement equivalence is the comparability of psychometric properties in the source and the

target (adapted) measures [25]. Questionnaire items do not always function equally in different cultural groups, and an item that behaves differently is said to exhibit a cross-cultural bias or differential item function (DIF) with respect to culture [26–28]. Since measurement equivalence is the basic requirement for comparing data across cultural groups, it is important to: (1) assess the construct validity of the adapted questionnaire and (2) examine and account for cross-cultural bias in the translated questionnaire [26, 28]. Rasch analysis is the method by which both construct validity and cross-cultural DIF can be assessed [27–29]. The aim of this study was to undertake a cross-cultural adaptation of the ENAT into Polish and then use Rasch analysis to validate the adapted tool (Pol-ENAT) in RA and SSc.

## Methods

### Design

This was a cross-sectional study conducted in two phases: (1) cross-cultural adaptation of the ENAT into Polish and (2) validation of the adapted tools (Pol-ENAT) in RA and SSc. The first (adaptation) phase followed standardized guidelines for cross-cultural adaptation of patient-reported outcome measures suggested by Beaton et al. [21]. The second phase was conducted using a cross-sectional survey design requiring patient completion of the adapted versions of the ENAT on one occasion, then subjecting the data to Rasch analysis to assess the construct validity, reliability and cross-cultural invariance of the translated tools. Ethical approval was obtained from the local ethics committee.

### Measures

The ENAT is a simple patient-completed questionnaire, which comprises 39 items grouped into the following 7 domains: managing pain (6 items), movement (5 items), feelings (4 items), arthritis process (7 items), treatments (7 items), self-help measures (6 items) and support systems (4 items). Items are Likert scales ranging from 0—"not important at all" to 4—"extremely important". The ENAT is used as a 'generic' tool across rheumatic diseases but the term 'arthritis' is replaced by 'rheumatic disease' when used in SSc. The descriptions of how the ENAT is used and scored are given in the online supplementary material.

### Phase 1: Cross-cultural adaptation

The original (English) ENAT was translated into Polish using the cross-cultural adaptation process described by Beaton et al. [21]. The process comprises five stages:

Forward translation, synthesis of the translations, back-translation, expert committee assessment and field testing.

The first (forward) translation stage from English (source language) into Polish (target language) was carried out by two independent translators whose mother tongue was Polish. The first translator was a professional bilingual translator (SS), and the second was a bilingual lay person (TS). Each translator produced a written report, (T1 and T2) of his translation, highlighting difficult phrases or uncertainties along with the rationale for their word choices.

A third unbiased person was added to the team (JS), whose role was to serve as a mediator in the discussion of translation differences arising from T1 and T2. Working from the original questionnaire as well as from the first (T1) and the second translator's (T2) version, one common translation (T-12) was produced together with a report documenting the process and how issues were resolved.

Back-translation stage was undertaken by two bilingual 'back-translators' (MK and PD) whose mother tongue was English and totally blind to the original versions. They worked from the T-12 version of the ENAT, producing English translations (BT1 and BT2). This is a process of validity checking to ensure the translated version accurately reflects the item content of the original version.

The composition of the expert committee included a methodologist, health professionals, all the (forward and backward) translators and the translation synthesis recorder. The original developer of the questionnaire was also included. The expert committee consolidated all the versions and components of the questionnaire and all translated versions (T1, T2, T12, BT1, BT2), discussing discrepancies raised in previous stages, and a consensus was reached on all items. The prefinal version of the ENAT was produced for field testing.

The field test of the adapted ENAT comprised 30 patients (15 with RA and 15 with SSc) recruited from the rheumatology outpatient clinics at one of the recruiting centres. They completed the Pol-ENAT unaided; then, they were interviewed to probe what they thought was meant by each questionnaire item and their response. Both the meaning of the items and responses were explored. A summary of issues raised in the translation for each item is presented in Table 2.

## Phase 2: Cross-cultural validation

The final translated versions of the ENAT (for RA and SSc) were then completed by a consecutive sample of patients fulfilling the above-mentioned inclusion criteria. The ENATs were anonymous but contained patients' demographical data such as gender, age, educational background and self-reported disease duration. Once completed, the data were entered into an IBM SPSS

database (version 19) [30] and subsequently subjected to Rasch analysis RUMM2030 software [31].

## Participants

Patients were recruited from rheumatology outpatient clinics at seven rheumatology centres in Poland. The inclusion criteria were: (1) positive diagnosis of either RA (using the ACR and the ACR/EULAR classification criteria for [32, 33]) or SSc (2) aged 18 years or above and (3) willingness to complete and return a questionnaire. The exclusion criteria were: (1) inability to complete the ENAT unaided and (2) having more than one form of rheumatic disease. The patients in the SSc group had articular symptoms such as pain, stiffness and movement impairment. Matching datasets of patients with RA and SSc from the UK were used in the analysis stage to test the cross-cultural invariance. This would inform whether the ENAT works in the same manner when completed by patients with the same disease in English or in Polish (the adapted version).

## Data analysis

Since the original (English) ENAT and other language versions have been shown to fit the Rasch model after correction for local dependency [18, 19], we used Rasch analysis in this study to test whether Pol-ENAT had retained its psychometric properties following the adaptation process. For this analysis, we used the Master's Partial Credit Model parameterization [34] in RUM2030 software [31]. Each Pol-ENAT item was assessed for 'fit' to the Rasch model, and then, the scale was assessed as a 39-item construct and as a 7-domain construct. In addition to fit statistics, the scales were tested for internal consistency, unidimensionality and DIF. The expected values for perfect model fit are presented at the bottom of tables of results. DIF analysis can be carried out efficiently along with other psychometric tests within the framework of Rasch models. Rasch analysis was used to test the evidence of cross-cultural DIF, to quantify the DIF and to calibrate a DIF-adjusted interval-level scale [27, 35]. Where cross-cultural DIF (between the Polish and UK datasets) was found, a DIF-adjusted scale was calibrated for use when data pooling from the two countries is desired.

## Results

### Patient characteristics

The validation study sample comprised 278 patients with RA ( $n = 145$ ) and SSc ( $n = 133$ ). Their mean (SD) age,

**Table 1** Patient characteristics

|                           | Poland                  |                          | UK                      |                          |
|---------------------------|-------------------------|--------------------------|-------------------------|--------------------------|
|                           | RA<br>( <i>n</i> = 145) | SSc<br>( <i>n</i> = 133) | RA<br>( <i>n</i> = 125) | SSc<br>( <i>n</i> = 128) |
| Mean age (SD)             | 52.79<br>(13.05)        | 53.89<br>(14.26)         | 56.26<br>(13.24)        | 54.44<br>(12.07)         |
| Disease duration<br>(SD)  | 13.36<br>(9.84)         | 10.84<br>(10.34)         | 13.55<br>(9.52)         | 14.34<br>(11.49)         |
| % Female                  | 82.1                    | 88.7                     | 79.2                    | 79.7                     |
| % Only basic<br>education | 9.7                     | 10.5                     |                         |                          |

SD standard deviation, RA rheumatoid arthritis, SSc systemic sclerosis

disease duration and gender distribution are summarized in Table 1. The cross-cultural validation phase included comparison of datasets of UK patients with RA and SSc, and their patient characteristics are also summarized in Table 1.

### Adaptation into Polish

Issues around translation included: multiple meanings of certain concepts, grammatical difficulties and inexactness or idiomatic expressions. Other issues were due to differences in the style of formulating questionnaire items in English and in Polish. The translators and the expert committee solved all the above problems by finding Polish equivalents, which would be understandable but also accurate from a medical point of view. A summary of issues arising from the back-translations and the agreements for each ENAT item (for RA) are presented in Table 2. The Expert Committee believes that the aim of proposing an accurate Polish version of the ENAT has been achieved.

### Cross-cultural validation phase

Table 3 presents fit statistics for individual items and for each subscale, i.e. pain, movement and feelings. A significant chi-square probability suggests a departure from the model. Most items in both the RA and SSc datasets were found to fit the model.

Despite the generally good individual item fit within each of the domains, when the scale is assessed as a singular 39-item construct, the model fit suggests significant deviation from the Rasch model (Table 4, analysis 1). Further investigation revealed the major cause of this misfit to be multiple significant residual correlations between items, therefore indicating local dependency. The pattern of the residual correlations suggested that the dependency clustered within each of the separate domains; therefore, the items were grouped within their respective domains and

treated as domain-level items (or testlets). This approach corrected for the local dependency within the domains, and subsequent analyses (Table 4, analysis 2 for the Polish, UK and the pooled datasets) resulted into fit to the model and satisfied the strict test for unidimensionality. The internal consistency was above the value of 0.7, which is a required value for group use [36].

### Cross-cultural invariance

Polish Educational Needs Assessment Tool was invariant to age, gender, disease duration and education background. The pooled dataset for RA revealed a cross-cultural DIF where Polish patients were more likely to have higher scores on ‘pain’ and ‘disease process’ and lower scores on ‘treatments’ and ‘support’ than their UK counterparts. The SSc-pooled datasets revealed cross-cultural DIF in only one subscale—‘support’ where the Polish patients were more likely to have higher scores than their UK counterparts. The cross-cultural DIF patterns and their significance are presented in Fig. 1. This finding means that adjustment for the cross-cultural bias is required if the data from Poland are pooled or compared with the UK data.

The Pol-ENAT raw scores for each of the seven subscales (which are ordinal in nature) were Rasch-transformed to calibrate interval-level scales with which data can be transformed. The conversion charts for the Polish data (RA and SSc) are presented in the online supplementary tables S1 and S2. Separate DIF-adjusted tables for comparison between the UK and Polish data are presented in online supplementary tables S3 and S4. The instruction on how to use the conversion charts is given in the online supplementary material.

## Discussion

Patient education should be an integral part of the care of people with rheumatic conditions [6, 10]. Our research has provided a valid tool with which clinicians in Poland can assess the educational needs of patients with RA and SSc. This assessment is likely to lead to provision of targeted and patient-centred education. When used for clinical purposes, the Pol-ENAT does not need scoring as the clinician can easily tell the items that are rated by the patient as ‘extremely important’. However, when used as an outcome measure, then the Pol-ENAT has satisfied psychometric standards to enable meaningful summation of scores within each domain. The tool has been found to have sufficient cross-cultural validity to enable data pooling and comparisons between Poland and the UK.

Although it is generally accepted that simple translation of a questionnaire into another language is not appropriate,

**Table 2** Back-translation, issues and agreements for each ENAT item

| Original  | Back-translation 1 (BT1)  | Back-translation 2 (BT2)  | Issues   | Agreement   |
|---|---|---|--|---|
| Arthritis Educational Needs Assessment Tool   | “Assessment Tools for Educational Needs of Patients with Arthritis”   | “A tool for assessing educational needs of patients with arthritis related”                                       | Uncertainty word whether “tools” or “tool” should in be used in Polish version<br>Discussion on the Polish multiple meaning of word “arthritis”<br>Also, there were differences in translation of the term “arthritis” | “Narzędzie do oceny potrzeb edukacyjnych pacjentów związanych z zapaleniem stawów”<br>The chosen term “zapalenie stawów” is the most adequate translation.  |
| How long have you had your arthritis for?   | “How long have you had arthritis?”  | “How long have you suffered from arthritis?”  | Uncertainty whether word “suffer” is appropriate   | “Jak długo choruje Pani/Pan na zapalenie stawów ?”<br>The Polish translation is correct in terms of style.  |
| Please state your age in years:   | “Please state your age”   | “Please state your age”   | Discussion whether phrase “in years” should be added   | “Proszę podać swój wiek.”<br>The phrase “in years” has been omitted.  |
| How old were you when you left school?  | “How old were you when you finished with formal education?”   | “How old were you when you finished school education?”  | Customary question concerning education in Polish does not require information about age   | “Proszę podać swoje wykształcenie.”<br>The most correct Polish phrase has been chosen.  |
| At this time, do you want education about anything to help you deal with your arthritis?  | Would you currently like to receive information which will help you manage your arthritis?                                    | Are you interested in getting information that will help you cope with arthritis?                                 | Uncertainty how to translate into Polish “manage”, “cope with” and “education”   | “Czy obecnie chciałaby Pani/Pan zdobyć informacje które pomogą Pani/Panu radzić sobie z zapaleniem stawów?”<br>Polish translation is correct in terms of style and grammar.                               |
| If yes, what?   | “If yes, what information would you like to receive?”   | “If so, what would you like to know?”   | More formally correct version of question in Polish should be given  | “Jeśli tak, to czego chciałaby Pani/Pan się dowiedzieć?”<br>Polish version is correct in terms of style.  |
| In general, how much information do you want about your arthritis?  | “In general, how much would you like to know about your rheumatic disease?”   | “Generally speaking, how much would you like to know about your rheumatism?”                                      | Discussion on word choice between “rheumatic disease” and “rheumatism”   | “Ogólnie rzecz biorąc, jak dużo chciałaby się Pani/Pan dowiedzieć o swojej chorobie reumatycznej?”<br>Polish version applies the term “rheumatic disease”   |
| How much do you need to know <u>now</u> about each of the following things? Please tick in the column that shows best how you feel: | “How much would you like to know <u>right now</u> about the following issues? Please mark the appropriate column with an ‘X’” | “How much would you/ you already know about the following issues? Please place a cross in the appropriate column” | Discussion concerning the phrase “please place a cross in the appropriate column”  | “Jak wiele chciałaby Pani/Pan wiedzieć <u>już teraz</u> na temat następujących zagadnień? Proszę o postawienie krzyżyka w odpowiedniej kolumnie.”<br>The most adequate Polish equivalent has been chosen. |
| This section relates to managing pain   | “Section on managing pain”  | “The section on coping with pain”   | Discussion whether to choose less or more formal way of introducing a new section of questions   | “Sekcja dotycząca radzenie sobie z bólem.”<br>A more formal way of introducing a new section has been chosen.   |

Table 2 continued

| Original  | Back-translation 1 (BT1)   | Back-translation 2 (BT2)   | Issues  | Agreement   |
|---|--|--|---|---|
| How important is it for you to know more about the following:                   | How important is knowing more about the following issues for you?                                  | How important is it for you/you would know more about the following issues?                              | Discussion whether choose less or more formal way of asking a question  | “Jak ważne jest dla Pani/Pana by wiedzieć więcej o następujących zagadnieniach.”<br>A formal way of asking a question has been chosen.  |
| Using exercise  | “Gymnastic exercise”   | “Physical exercises”   | Uncertainty whether “gymnastic” and “physical” can be used synonymic  | “Ćwiczenia gimnastyczne”<br>Polish version is correct in terms of style.  |
| This section relates to movement  | “Section on issues related to moving around”   | “The section on issues related to mobility”  | Discussion whether to choose less or more formal way of introducing a new section of questions                                    | “Sekcja dotycząca zagadnień związanych z poruszaniem się.”<br>The most adequate Polish version has been chosen  |
| Ways to do things which wear my joints less                                     | “Methods of reducing wear of/relieving joints”   | “Methods of relieving joints”  | English idiomatic expression “wear joints less” was replaced with a Polish idiomatic phrase “oszczędzać satwy” (In English: save) | “Metody oszczędzania/ odciążania stawów”  |
| Ways to deal with moods or depression   | “Methods to help manage mood changes or depressive states”   | “Ways to cope with moods or periods of depression”   | Ambiguous meaning of a term “moods”   | “Sponsor radzenia sobie ze zmiennością nastrojów lub stanami depresji.”<br>The chosen term „zmiennosc nastrojów” means frequent changes in mood   |
| Why I am feeling down or depressed  | “Why do I feel down or depressed?”   | “Why do I feel moody or depresses?”  | Ambiguous meaning of the term “be depressed”  | “Dlaczego czują się przygnębiona/y, czy depresyjna/y”<br>The chosen term „depresyjny” relates to a state of depression.   |
| How arthritis might affect my children or relatives                             | “Can the disease have an effect on the lives of my children and close ones?”                       | “Can the disease affect the lives of my children and family?”  | Multiple meaning of word “affect”   | “Czy choroba może mieć wpływ na życie moich dzieci i bliskich?”<br>The chosen phrase „wpływ na życie” relates to quality of life  |
| What might happen in the future   | “How will my condition change in the future?”  | “How will my condition change in the future?”  | The question is open to various interpretations   | “Jak mój stan będzie się zmieniał w przyszłości?”<br>The translation focuses on patient’s personal condition in the future  |
| This section is about treatments you may be receiving from health professionals | “Section on methods of treatment that you can receive from nurses and other medical professionals” | “The section concerns treatments that the patient can receive from nurses and other health care workers” | Lack of a Polish equivalent of a term “health professionals”  | “Secant dotycząca sposobów leczenia, które Pani/Pan może otrzymać od pielęgniarki i innych pracowników ochrony zdrowia.”<br>The chosen phrase describes the meaning of “health professionals” |

Table 2 continued

| Original   | Back-translation 1 (BT1)  | Back-translation 2 (BT2)  | Issues   | Agreement  |
|--|---|---|--|--|
| How an operation might help me                               | “Can surgery help me?”  | “Can surgery help me?”  | Uncertainty whether word “surgery” or “operation” should be used   | “Czy zabieg chirurgiczny może mi pomóc?”<br>The most adequate Polish term has been chosen.   |
| What the side effects of my medicines are                    | “What are adverse side effects of medicines?”                           | “Are there side effects to the medication?”                                     | Uncertainty whether the question should be more general or relate to condition of the particular patient                 | “Jakie są działania niepożądane leków które przyjmuję?”<br>The chosen phrase relates to patient’s condition.   |
| How appliances might help me (splints, adaptations, collars) | “What devices may help me (orthopaedic collars, splints, stabilizers)?” | “What appliances can help me (e.g. orthopaedic collars, splints, stabilizers)?” | Difficulty with translating term “adaptations”   | “Jakie przyrządy i/lub udogodnienia mogą mi pomóc (np. kołnierze ortopedyczne, szyny, specjalnie dostosowane poręcze, etc.)?”<br>A descriptive phrase explaining the term “adaptation” has been chosen |
| Foods or vitamins that might help                            | “Diet or vitamins which may help”                                       | “Diet or vitamins that may help”  | Uncertainty whether “foods” relates to “diet”  | “Produkty pokarmowe lub witaminy które mogą pomóc”<br>The chosen term “produkty pokarmowe” means foods   |
| Exercises I should be doing                                  | “Recommended motion exercises”  | “Recommended physical exercises”  | Uncertainty whether word “recommended” should be used  | “Zalecane ćwiczenia”<br>The most adequate Polish translation has been chosen   |
| How much exercise I should be doing                          | “Frequency of performing motion exercises”                              | “The frequency of physical exercises”   | Uncertainty whether the word “frequency” is adequate   | “Częstotliwość wykonywania ćwiczeń ruchowych”<br>The chosen term “częstotliwość” means frequency   |
| Times when I should call the doctor or nurse                 | “Situations when I should contact a doctor or nurse”                    | “In what situations, should I consult a doctor or nurse?”                       | Uncertainty whether “situations” is the correct translation of the word “times”  | “Sytuacje w których powinienam/nieniem skontaktować się z lekarzem lub pielęgniarką?”<br>Polish translation is correct in terms of grammar and style   |
| Organizations I can get in touch with about arthritis        | “Organizations which can help patients with rheumatic diseases?”        | “Organizations that can help patients with rheumatic diseases”                  | Ambiguous meaning of term “organization” also there is an ambiguous meaning of idiomatic expression “get in touch with.” | “Stowarzyszenia które mogą pomóc pacjentom z chorobami reumatycznymi.”<br>Polish phrase describing contacting an organist has been chosen  |
| Who I can ask about financial help                           | “Who can I ask for financial help?”                                     | “Who can I ask about financial assistance?”                                     | Lack of cultural equivalence (it is not possible to ask for financial help in case of suffering from arthritis)          | “Kogo mogę poprosić o pomoc finansową?”  |

**Table 2** continued

| Original  | Back-translation 1 (BT1)  | Back-translation 2 (BT2)  | Issues   | Agreement   |
|---|---|---|--|---|
| Where I can find groups who will help me to cope with arthritis | “Where can I find support groups for people with rheumatic diseases?”               | “Where can I find support groups for people with rheumatic diseases?” | Uncertainty whether “groups” means the same as “support groups”                        | “Gdzie mogę znaleźć grupy wsparcia dla osób z chorobami reumatycznymi?”<br><br>The term related to help groups has been used                                |
| How I can get the most out of seeing the doctor or nurse        | “How can I improve communication with doctors or nurses to maximize effectiveness?” | “How to make more effective contacts with a doctor or nurse?”         | Idiomatic expression “get the most out of” can be translated in various ways in Polish | “Jakeeeeeee sprawić by kontakty z lekarzem lub pielęgniarzką były najbardziej efektywne?”<br><br>The word “efektywne” (in English: effective) has been used |

**Table 3** Fit statistics for individual items and subscales (testlets)

| Items      | RA  |       |      |       |          |       |             | SSc   |      |       |          |       |             |
|------------|-----|-------|------|-------|----------|-------|-------------|-------|------|-------|----------|-------|-------------|
|            | Loc | SE    | FR   | DF    | $\chi^2$ | *P    | Loc         | SE    | FR   | DF    | $\chi^2$ | *P    |             |
| Pain       | 1   | -1.09 | 0.12 | 0.45  | 130.49   | 0.13  | 0.94        | -0.84 | 0.11 | -0.47 | 122.69   | 1.43  | 0.49        |
|            | 2   | -0.01 | 0.10 | 1.15  | 130.49   | 0.79  | 0.67        | -0.13 | 0.09 | 0.64  | 122.69   | 1.04  | 0.59        |
|            | 3   | -0.20 | 0.10 | 0.80  | 130.49   | 3.66  | 0.16        | 0.10  | 0.09 | -0.07 | 122.69   | 4.11  | 0.13        |
|            | 4   | 0.20  | 0.10 | 1.66  | 130.49   | 5.19  | 0.07        | -0.03 | 0.09 | 1.00  | 122.69   | 0.64  | 0.73        |
|            | 5   | -0.17 | 0.10 | 0.44  | 130.49   | 1.21  | 0.54        | -0.21 | 0.09 | 1.64  | 122.69   | 7.99  | 0.02        |
|            | 6   | 0.13  | 0.09 | 3.58  | 130.49   | 4.27  | 0.12        | 0.02  | 0.09 | 2.71  | 122.69   | 12.27 | <b>0.00</b> |
| Movement   | 7   | 0.71  | 0.10 | 4.86  | 130.49   | 30.85 | <b>0.00</b> | 0.65  | 0.08 | 2.13  | 122.69   | 2.81  | 0.25        |
|            | 8   | 0.76  | 0.10 | 1.71  | 130.49   | 8.48  | 0.01        | 0.57  | 0.08 | 1.09  | 122.69   | 1.41  | 0.50        |
|            | 9   | 0.22  | 0.10 | 2.47  | 130.49   | 6.17  | 0.05        | 0.49  | 0.09 | 0.92  | 122.69   | 0.08  | 0.96        |
|            | 10  | 0.16  | 0.10 | 0.97  | 130.49   | 1.29  | 0.52        | 0.15  | 0.09 | -0.18 | 122.69   | 0.40  | 0.82        |
|            | 11  | -0.76 | 0.12 | -1.02 | 130.49   | 2.86  | 0.24        | -0.08 | 0.08 | -0.28 | 122.69   | 0.04  | 0.98        |
| Feelings   | 12  | -0.06 | 0.10 | -0.33 | 130.49   | 2.86  | 0.24        | 0.09  | 0.09 | 0.13  | 122.69   | 0.65  | 0.72        |
|            | 13  | 0.31  | 0.10 | 0.03  | 130.49   | 1.87  | 0.39        | 0.17  | 0.08 | 1.80  | 122.69   | 0.61  | 0.74        |
|            | 14  | 0.10  | 0.10 | -0.92 | 130.49   | 0.59  | 0.74        | 0.09  | 0.09 | 0.11  | 122.69   | 0.68  | 0.71        |
|            | 15  | 0.41  | 0.09 | 0.59  | 130.49   | 0.93  | 0.63        | 0.36  | 0.08 | 1.66  | 122.69   | 0.32  | 0.85        |
| Disease    | 16  | -0.27 | 0.09 | 3.91  | 130.49   | 8.56  | 0.01        | -0.33 | 0.09 | 1.68  | 122.69   | 2.42  | 0.30        |
|            | 17  | 0.18  | 0.09 | 0.07  | 130.49   | 0.11  | 0.95        | 0.17  | 0.08 | 0.59  | 122.69   | 0.64  | 0.73        |
|            | 18  | -0.32 | 0.09 | -0.02 | 130.49   | 3.01  | 0.22        | -0.32 | 0.08 | 1.54  | 122.69   | 0.15  | 0.93        |
|            | 19  | -0.90 | 0.11 | -0.82 | 130.49   | 1.36  | 0.51        | -0.28 | 0.08 | 0.67  | 122.69   | 0.56  | 0.75        |
|            | 20  | -0.27 | 0.10 | -2.07 | 130.49   | 2.37  | 0.31        | -0.11 | 0.08 | -1.10 | 122.69   | 2.63  | 0.27        |
|            | 21  | 0.21  | 0.09 | 0.62  | 130.49   | 0.64  | 0.73        | 0.00  | 0.09 | -1.45 | 122.69   | 6.23  | 0.04        |
|            | 22  | -0.59 | 0.10 | -0.19 | 130.49   | 0.38  | 0.83        | -0.58 | 0.09 | -0.53 | 122.69   | 1.83  | 0.40        |
| Treatments | 23  | 0.27  | 0.09 | -0.57 | 130.49   | 4.65  | 0.10        | 0.09  | 0.09 | 0.81  | 122.69   | 0.93  | 0.63        |
|            | 24  | -0.01 | 0.09 | -0.39 | 130.49   | 1.95  | 0.38        | 0.06  | 0.08 | -0.08 | 122.69   | 0.74  | 0.69        |
|            | 25  | -0.42 | 0.09 | -2.26 | 130.49   | 6.29  | 0.04        | -0.21 | 0.09 | 0.93  | 122.69   | 2.26  | 0.32        |
|            | 26  | 0.22  | 0.09 | -1.76 | 130.49   | 1.84  | 0.40        | 0.05  | 0.09 | -0.17 | 122.69   | 0.42  | 0.81        |
|            | 27  | 0.17  | 0.09 | -1.77 | 130.49   | 1.18  | 0.56        | -0.01 | 0.09 | -0.53 | 122.69   | 1.83  | 0.40        |
|            | 28  | 0.11  | 0.09 | 1.67  | 130.49   | 0.40  | 0.82        | 0.45  | 0.08 | 0.50  | 122.69   | 3.43  | 0.18        |
|            | 29  | 0.21  | 0.09 | 3.10  | 130.49   | 2.10  | 0.35        | 0.55  | 0.08 | -0.04 | 122.69   | 0.25  | 0.88        |

**Table 3** continued

| Items           | RA    |       |       |        |          |      |       | SSc   |       |        |          |      |      |
|-----------------|-------|-------|-------|--------|----------|------|-------|-------|-------|--------|----------|------|------|
|                 | Loc   | SE    | FR    | DF     | $\chi^2$ | *P   | Loc   | SE    | FR    | DF     | $\chi^2$ | *P   |      |
| Self-help       | 30    | 0.32  | 0.10  | 1.80   | 130.49   | 1.59 | 0.45  | 0.19  | 0.09  | 3.02   | 122.69   | 9.87 | 0.01 |
|                 | 31    | -0.28 | 0.10  | -1.09  | 130.49   | 0.92 | 0.63  | -0.33 | 0.10  | 0.48   | 122.69   | 0.16 | 0.92 |
|                 | 32    | -0.25 | 0.10  | -2.06  | 130.49   | 7.26 | 0.03  | -0.46 | 0.10  | -1.18  | 122.69   | 6.68 | 0.04 |
|                 | 33    | -0.42 | 0.10  | -1.93  | 130.49   | 8.24 | 0.02  | -0.34 | 0.10  | -1.17  | 122.69   | 6.02 | 0.05 |
|                 | 34    | -0.19 | 0.10  | -2.30  | 130.49   | 8.88 | 0.01  | -0.24 | 0.10  | -0.89  | 122.69   | 8.40 | 0.02 |
|                 | 35    | 0.05  | 0.09  | -2.23  | 130.49   | 2.50 | 0.29  | -0.27 | 0.09  | -2.01  | 122.69   | 9.19 | 0.01 |
| Support         | 36    | 0.28  | 0.10  | 0.88   | 130.49   | 2.48 | 0.29  | 0.07  | 0.09  | 0.54   | 122.69   | 0.83 | 0.66 |
|                 | 37    | 0.42  | 0.09  | -0.34  | 130.49   | 3.94 | 0.14  | 0.29  | 0.09  | 0.68   | 122.69   | 0.02 | 0.99 |
|                 | 38    | 0.57  | 0.10  | -1.28  | 130.49   | 4.53 | 0.10  | 0.33  | 0.09  | -0.01  | 122.69   | 0.74 | 0.69 |
|                 | 39    | 0.19  | 0.09  | -1.90  | 130.49   | 4.95 | 0.08  | -0.16 | 0.09  | -0.98  | 122.69   | 3.85 | 0.15 |
| <b>Testlets</b> |       |       |       |        |          |      |       |       |       |        |          |      |      |
| Pain            | -0.12 | 0.03  | 2.45  | 114.43 | 3.28     | 0.19 | -0.09 | 0.02  | 0.02  | 107.57 | 0.61     | 0.74 |      |
| Movements       | 0.11  | 0.03  | 1.20  | 114.43 | 1.88     | 0.39 | 0.12  | 0.02  | 1.47  | 107.57 | 0.58     | 0.75 |      |
| Feelings        | 0.04  | 0.03  | 0.27  | 114.43 | 1.23     | 0.54 | 0.04  | 0.03  | 1.78  | 107.57 | 0.41     | 0.82 |      |
| Disease         | -0.12 | 0.02  | -0.36 | 114.43 | 0.26     | 0.88 | -0.11 | 0.02  | 0.14  | 107.57 | 0.84     | 0.66 |      |
| Treatments      | 0.00  | 0.02  | -0.41 | 114.43 | 2.81     | 0.25 | 0.09  | 0.02  | 1.06  | 107.57 | 0.62     | 0.73 |      |
| Self-help       | -0.07 | 0.03  | -2.60 | 114.43 | 4.33     | 0.11 | -0.08 | 0.02  | -0.29 | 107.57 | 1.64     | 0.44 |      |
| Support         | 0.15  | 0.03  | -0.55 | 114.43 | 3.18     | 0.20 | 0.04  | 0.03  | -0.40 | 107.57 | 3.44     | 0.18 |      |


Loc location, SE standard error, FR fit residuals, DF degrees of freedom, RA rheumatoid arthritis, SSc systemic sclerosis,  $\chi^2$  chi square

\* Bonferroni adjusted  $p$  value  $> 0.0013$  for model fit (i.e. 0.05/39 tests) or  $p > 0.0071$  for subscale model fit (i.e. 0.05/7 tests)

**Table 4** Fit statistics indicating item fit, person fit and unidimensionality of the 7-domain scales in SSc and RA disease groups

| Disease group                | Country | Analyses     | Item fit residual |       | Person fit residual |       | Chi-square interaction |        | PSI   | Independent $t$ tests (95 % CI) |
|------------------------------|---------|--------------|-------------------|-------|---------------------|-------|------------------------|--------|-------|---------------------------------|
|                              |         |              | Mean              | SD    | Mean                | SD    | Value ( $df$ )         | $p$    |       |                                 |
| SSc                          | Poland  | Analysis 1   | 0.362             | 1.142 | -0.411              | 2.312 | 104.562 (78)           | 0.024  | 0.947 |                                 |
|                              |         | Analysis 2   | 0.540             | 0.883 | -0.329              | 1.233 | 8.132 (14)             | 0.882  | 0.855 | 0.046 (0.008, 0.083)            |
|                              | UK      | Analysis 1   | 0.319             | 1.524 | -0.330              | 2.105 | 54.951 (39)            | 0.047  | 0.933 |                                 |
|                              |         | Analysis 2   | 0.391             | 0.723 | -0.336              | 1.166 | 7.439 (7)              | 0.385  | 0.816 | 0.056 (0.018, 0.094)            |
|                              | Pooled  | Analysis 1   | 0.434             | 1.913 | -0.441              | 2.302 | 226.122 (156)          | <0.001 | 0.940 |                                 |
|                              |         | Analysis 2   | 0.567             | 0.598 | -0.368              | 1.220 | 24.189 (28)            | 0.672  | 0.829 | 0.056 (0.029, 0.084)            |
|                              |         | DIF-adjusted | 0.520             | 0.559 | -0.356              | 1.218 | 33.259 (32)            | 0.406  | 0.838 |                                 |
| RA                           | Poland  | Analysis 1   | 0.142             | 1.826 | -0.556              | 2.429 | 151.258 (78)           | <0.001 | 0.959 |                                 |
|                              |         | Analysis 2   | 0.000             | 1.573 | -0.428              | 1.213 | 16.953 (14)            | 0.259  | 0.894 | 0.069 (0.034, 0.105)            |
|                              | UK      | Analysis 1   | 0.288             | 1.868 | -0.250              | 2.133 | 101.958 (39)           | <0.001 | 0.932 |                                 |
|                              |         | Analysis 2   | 0.236             | 0.953 | -3.955              | 1.290 | 6.392 (7)              | 0.495  | 0.857 | 0.069 (0.046, 0.143)            |
|                              | Pooled  | Analysis 1   | 0.041             | 2.637 | -0.450              | 2.455 | 345.946 (117)          | <0.001 | 0.954 |                                 |
|                              |         | Analysis 2   | -0.003            | 1.646 | -0.440              | 1.258 | 28.143 (21)            | 0.136  | 0.885 | 0.067 (0.041, 0.093)            |
|                              |         | DIF-adjusted | 0.163             | 1.151 | -0.441              | 1.273 | 28.971 (33)            | 0.668  | 0.890 |                                 |
| Requirements for perfect fit |         |              | 0                 | 1     | 0                   | 1     |                        | >0.05  | >0.7  | Lower-bound 95 % CI < 0.05      |

Analysis 1 preliminary analysis with 39 items, Analysis 2 analysis of subscales (testlets), SD standard deviation,  $df$  degrees of freedom, \*  $p$  value  $> 0.5$  for model fit, PSI person separation index



**Fig. 1** Cross-cultural DIF at domain (testlet) level in the RA and SSc disease groups. *RA* rheumatoid arthritis, *SSc* systemic sclerosis. **a** Pain (RA), **b** disease process (RA), **c** Treatments (RA), **d** Support (RA), **e** Support (SSc)

there is no consensus on the best method for cross-cultural adaptation [37]. The current adaptation methods either use a ‘forward–backward’ translation or a ‘forward only’ translation. In this research, we have used the Beaton’s method [21], which utilizes ‘forward–backward’ translation. Proponents of a ‘forward only’ approach [38, 39] suggest that back-translation would cast doubt over the abilities of the forward translators, producing unmanageable amount of text and little information of any value. In our experience, the ‘forward–backward’ process has been valuable as evidenced in the results. The expert committee meeting and a field test with patients ensured thoroughness in translation, and a conceptual equivalence between the English and the Polish version of the ENAT was achieved. It is likely that other methods utilizing a ‘forward–backward’ translation [22–24, 40, 41] would have achieved similar results.

This study has demonstrated that several items did not achieve a ‘linguistic equivalence’ or ‘idiomatic equivalence’, and more cultural-specific terms had to be used to ensure that they are understood by the target population (Table 2). Even when the adaptation process is successful to an extent of achieving a linguistic equivalence, this does not guarantee construct validity and reliability or ‘measurement equivalence’ [26–29]. For this reason, Kucukdeveci et al. [35] have suggested that a psychometric test of cross-cultural invariance should be incorporated into the standard adaptation process, so that problematic items may be reviewed in the translation process.

Subjecting the adapted Pol-ENAT to Rasch analysis ensured that the measurement properties (construct validity and reliability) of the ENAT were retained following the adaptation process. Calibration of the Pol-ENAT into an interval scale enables transforming the raw data into interval level for parametric analyses if required. While it is possible to have a valid and a reliable adapted instrument which works well in a given culture, when cross-cultural DIF is present, it means that the instrument works differently at least in some of the items (or subscales), which possess DIF [27]. Cross-cultural DIF may mean that the tools are valid for use only in their respective countries, but not for multinational data comparisons or data pooling. Alternatively, the tools may need to be adjusted for the identified cross-cultural DIF to enable cross-cultural data comparison(s). In this study, Rasch analysis has confirmed a level of the tools’ cross-cultural validity sufficient for use between Poland and the UK, and we have calibrated DIF-adjusted conversion tables for use where comparison of the Polish and the UK data is required. This approach has been used in the previous cross-cultural validation of the ENAT [18, 19] and other questionnaires [35, 42, 43], which are intended for multinational use.

This study has three main limitations. First, convenience sample was used, and it was obtained from only six centres,

therefore not necessarily representative of the whole Polish population. This is unlikely however to affect the conclusions of this study since Polish language has no major variations across the country and sample size requirements for Rasch analysis were adequately met. Second, the ENAT is a self-completed questionnaire, and consequently, it does not reach the population of patients who cannot read and write. Third, although the ENAT has been validated in other European countries [19], the DIF-adjusted conversion table developed in this research applies only to comparison between Poland and UK data. Comparisons with other countries can only take place when cross-cultural DIF patterns between Poland and those countries have been established. Future research should look into the impact of the advances in information and communication technologies and how tools such as Pol-ENAT could go beyond just assessment of needs, but also link patients with available and credible resources. Different versions of the ENAT can be obtained from the University of Leeds by following this link [http://medhealth.leeds.ac.uk/info/732/psychometric\\_laboratory/1493/scales](http://medhealth.leeds.ac.uk/info/732/psychometric_laboratory/1493/scales).

## Conclusion

Using a standard process in cross-cultural adaptation, conceptual equivalence was achieved between the original (UK) ENAT and the adapted Pol-ENAT. Fit to the Rasch model confirmed that the construct validity and internal consistency of the ENAT have been preserved. The scales have been calibrated to ensure psychometric equivalence when undertaking multinational research. The Pol-ENAT can be used with confidence in assessing the educational needs of patients with RA and SSc in Poland.

**Acknowledgments** This study was supported by a research grant from the Medical University of Białystok, Poland (UMB: 113-60967L). The authors wish to thank the following people: Małgorzata Bykowska-Sochacka—Dr. Jadwiga Titz-Kosko Regional Hospital for Rheumatic Diseases in Sopot, Poland. Sławomir Jeka—Department of Rheumatology and Connective Tissue Diseases, 2nd University Hospital in Bydgoszcz, Poland. Piotr Leszczyński—Department of Rheumatology and Rehabilitation, Medical University in Poznań, Poland. Maria Majdan—Department of Rheumatology and Connective Tissue Disease, Medical University in Lublin, Poland. Marzena Olesinska—Department of Connective Tissue Disease, Institute of Rheumatology in Warsaw, Poland. Wojciech Romanowski—Department of Poznań Centre of Rheumatology in Śrem, Poland.

**Conflict of interest** All authors have completed the Unified Competing Interest form at <http://www.icmje.org/conflicts-of-interest/> (available from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

## References

- Hakim, A., Clunie, G. P. R., & Haq, I. (2006). *Oxford handbook of rheumatology* (2nd ed.). Oxford: Oxford University Press.
- Wollheim, F. A. (2005). Classification of systemic sclerosis. Visions and reality. *Rheumatology (Oxford)*, *44*(10), 1212–1216.
- Hudson, M., Thombs, B. D., Steele, R., Panopalis, P., Newton, E., & Baron, M. (2009). Health-related quality of life in systemic sclerosis: A systematic review. *Arthritis and Rheumatism*, *61*(8), 1112–1120.
- Bombardier, C., Barbieri, M., Parthan, A., Zack, D. J., Walker, V., Macarios, D., et al. (2012). The relationship between joint damage and functional disability in rheumatoid arthritis: A systematic review. *Annals of the Rheumatic Diseases*, *71*(6), 836–844.
- Michaud, K., Vera-Llonch, M., & Oster, G. (2012). Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. *Journal of Rheumatology*, *39*(1), 54–59.
- Combe, B., Landewe, R., Lukas, C., Bolosiu, H. D., Breedveld, F., Dougados, M., et al. (2007). EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Annals of the Rheumatic Diseases*, *66*(1), 34–45.
- Ndosi, M., Lewis, M., Hale, C., Quinn, H., Ryan, S., Emery, P., et al. (2013). The outcome and cost-effectiveness of nurse-led care in people with rheumatoid arthritis: A multicentre randomised controlled trial. *Annals of the Rheumatic Diseases*, doi:10.1136/annrheumdis-2013-203403.
- van Eijk-Hustings, Y., Ammerlaan, J., Voorneveld-Nieuwenhuis, H., Maat, B., Veldhuizen, C., & Repping-Wuts, H. (2013). Patients' needs and expectations with regard to rheumatology nursing care: Results of multicentre focus group interviews. *Annals of the Rheumatic Diseases*, *72*(6), 831–835.
- Sierakowska, M., Krajewska-Kulak, E., Lewko, J., Przeorska-Najgebauer, T., Jankowiak, B., Rolka, H., et al. (2005). The education of patients with rheumatoid arthritis—the knowledge and expectation of patients—the opinions of rheumatology nurses. *Roczniki Akademii Medycznej w Białymstoku*, *50*(Suppl 1), 107–110.
- Zangi, H. A. (2014). The evidence for patient education in inflammatory arthritis. *Annals of the Rheumatic Diseases*, *73*(Suppl 2). doi:10.1136/annrheumdis-2014-eular.6128.
- Ackerman, I. N., Buchbinder, R., & Osborne, R. H. (2013). Factors limiting participation in arthritis self-management programmes: An exploration of barriers and patient preferences within a randomized controlled trial. *Rheumatology (Oxford)*, *52*(3), 472–479.
- Gronning, K., Rannestad, T., Skomsvoll, J. F., Rygg, L. O., & Steinsbekk, A. (2014). Long-term effects of a nurse-led group and individual patient education programme for patients with chronic inflammatory polyarthritis—a randomised controlled trial. *Journal of Clinical Nursing*, *23*(7–8), 1005–1017.
- Bode, C., Taal, E., Emons, P. A. A., Galetzka, M., Rasker, J. J., & Van de Laar, M. A. F. J. (2008). Limited results of group self-management education for rheumatoid arthritis patients and their partners: Explanations from the patient perspective. *Clinical Rheumatology*, *27*(12), 1523–1528.
- Koehn, C. L., & Esdaile, J. M. (2008). Patient education and self-management of musculoskeletal diseases. *Best Practice & Research Clinical Rheumatology*, *22*(3), 395–405.
- Li, L. C. (2007). If knowledge is power, why don't rheumatoid arthritis education programs show better outcomes? *Journal of Rheumatology*, *34*(8), 1645.
- Meesters, J., de Boer, I., van den Berg, M., Fiocco, M., & Vliet Vlieland, T. (2011). Unmet information needs about the delivery of rheumatology health care services: A survey among patients with rheumatoid arthritis. *Patient Education and Counseling*, *85*(2), 299–303.
- Hardware, B., Anne Lacey, E., & Shewan, J. (2004). Towards the development of a tool to assess educational needs in patients with arthritis. *Clinical Effectiveness in Nursing*, *8*(2), 111–117.
- Ndosi, M., Tennant, A., Bergsten, U., Kukkurainen, M. L., Machado, P., de la Torre-Aboki, J., et al. (2011). Cross-cultural validation of the Educational Needs Assessment Tool in RA in 7 European countries. *BMC Musculoskeletal Disorders*, *12*, 110.
- Ndosi, M., Bremander, A., Hamnes, B., Horton, M., Kukkurainen, M. L., Machado, P., et al. (2013). Validation of the educational needs assessment tool as a generic instrument for rheumatic diseases in seven European countries. *Annals of the Rheumatic Diseases*, doi:10.1136/annrheumdis-2013-203461.
- Hui, C. H., & Triandis, H. C. (1985). Measurement in cross-cultural psychology a review and comparison of strategies. *Journal of Cross-Cultural Psychology*, *16*(2), 131–152.
- Beaton, D. E., Bombardier, C., Guillemin, F., & Ferraz, M. B. (2000). Guidelines for the process of cross-cultural adaptation of self-report measures. *Spine (Phila Pa 1976)*, *25*(24), 3186–3191.
- Cull, A., Sprangers, M., Bjordal, K., Aaronson, N., West, K., Bottomley, A., et al. (2002). *EORTC quality of life group translation procedure*. Brussels: EORTC.
- Wild, D., Grove, A., Martin, M., Eremenco, S., McElroy, S., Verjee-Lorenz, A., et al. (2005). Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR task force for translation and cultural adaptation. *Value in Health*, *8*(2), 94–104.
- Bonomi, A. E., Cella, D. F., Hahn, E. A., Bjordal, K., Sperner-Unterweger, B., Gangeri, L., et al. (1996). Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. *Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation*, *5*(3), 309–320.
- Stewart, A. L., & Napoles-Springer, A. (2000). Health-related quality-of-life assessments in diverse population groups in the United States. *Medical Care*, *38*(9 Suppl), I1102–I1124.
- Mullen, M. R. (1995). Diagnosing measurement equivalence in cross-national research. *Journal of International Business Studies*, *26*(3), 573–596.
- Tennant, A., Penta, M., Tesio, L., Grimby, G., Thonnard, J. L., Slade, A., et al. (2004). Assessing and adjusting for cross-cultural validity of impairment and activity limitation scales through differential item functioning within the framework of the Rasch model: The PRO-ESOR project. *Medical Care*, *42*(1 Suppl), I37–I48.
- Brodersen, J., Meads, D., Kreiner, S., Thorsen, H., Doward, L., & McKenna, S. (2007). Methodological aspects of differential item functioning in the Rasch model. *Journal of Medical Economics*, *10*(3), 309–324.
- Bond, T. G., & Fox, C. M. (2001). *Applying the Rasch model: Fundamental measurement in the human sciences*. London: Lawrence Erlbaum Associates.
- IBM. (2010). IBM SPSS Statistics 19.0.1: SPSS Inc.
- Andrich, D., Lyne, A., Sheridan, B., & Luo, G. (2003). *RUMM 2020*. Perth: RUMM Laboratory.
- Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S., et al. (1988). The American

- Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis and Rheumatism*, 31(3), 315–324.
33. Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., et al. (2010). 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Annals of the Rheumatic Diseases*, 69(9), 1580–1588.
34. Masters, G. A. (1982). Rasch model for partial credit scoring. *Psychometrika*, 47, 149–174.
35. Kucukdeveci, A. A., Sahin, H., Ataman, S., Griffiths, B., & Tennant, A. (2004). Issues in cross-cultural validity: Example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. *Arthritis and Rheumatism*, 51(1), 14–19.
36. Tennant, A., & Conaghan, P. (2007). The rasch measurement model in rheumatology: What is it and why use it? When should it be applied, and what should one look for in a Rasch paper. *Arthritis and Rheumatism*, 57(8), 1358–1362.
37. Acquadro, C., Conway, K., Hareendran, A., Aaronson, N. (2008). European Regulatory Issues and Quality of Life Assessment (ERIQA) Group. Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. *Value in Health*, 11(3), 509–521.
38. McKenna, S. P., & Doward, L. C. (2005). The translation and cultural adaptation of patient-reported outcome measures. *Value in Health*, 8(2), 89–91.
39. Swaine-Verdier, A., Doward, L. C., Hagell, P., Thorsen, H., & McKenna, S. P. (2004). Adapting quality of life instruments. *Value in Health*, 7, S27–S30.
40. Hunt, S. M., Alonso, J., Bucquet, D., Niero, M., Wiklund, I., & McKenna, S. (1991). Cross-cultural adaptation of health measures. European group for health management and quality of life assessment. *Health Policy*, 19(1), 33–44.
41. Skevington, S. (2002). Advancing cross-cultural research on quality of life: Observations drawn from the WHOQOL development. *Quality of Life Research*, 11(2), 135–144.
42. Kutlay, S., Kucukdeveci, A. A., Gonul, D., & Tennant, A. (2003). Adaptation and validation of the Turkish version of the Rheumatoid Arthritis Quality of Life Scale. *Rheumatology International*, 23(1), 21–26.
43. Gijon-Nogueron, G., Ndosí, M., Luque-Suarez, A., Alcacer-Pitarch, B., Munuera, P. V., Garrow, A., et al. (2014). Cross-cultural adaptation and validation of the Manchester Foot Pain and Disability Index into Spanish. *Quality of Life Research*, 23(2), 571–579.